On GLP-1s Before Spine Surgery: Should You Stop or Stay the Course?

On GLP-1s Before Spine Surgery: Should You Stop or Stay the Course?

Here is something most surgeons are not yet telling their patients: according to new research, being on a GLP-1 receptor agonist like semaglutide or tirzepatide does not appear to make spine surgery more dangerous or less successful.

That flies in the face of what a lot of people are hearing in pre-op appointments right now.

Important: I'm not a doctor. Everything I share here is based on published research and is meant to help you have a smarter conversation with your healthcare team — not replace that conversation.

---

The Bottom Line

• A 2025 study published in PubMed found that patients on GLP-1 receptor agonists had no significant difference in spine surgery complications, infection rates, or recovery outcomes compared to patients not on these medications.
• The biggest real surgical risk tied to GLP-1s is aspiration during anesthesia — stomach contents coming up during intubation. That risk exists, but it is manageable with the right protocol.
• Blanket "stop your GLP-1 two weeks before surgery" advice is becoming outdated for many patients. The decision depends on your specific situation.
• If you are on a GLP-1 and have spine surgery coming up: do not stop or continue on your own. Use this article to ask your anesthesiologist and surgeon the specific questions listed below.
• For most people, the surgical risk calculus has shifted. The benefits of staying on your medication may outweigh the risks of stopping — but that call belongs to your care team.

---

Why People Are Confused About This

When GLP-1 medications like Ozempic and Wegovy exploded in popularity, anesthesiologists got nervous. These drugs slow gastric emptying — meaning food and liquid sit in your stomach longer than normal. During general anesthesia, that raises the risk of aspirating stomach contents into your lungs.

The American Society of Anesthesiologists issued guidance in 2023 suggesting patients pause GLP-1s before elective procedures. That guidance got passed around like gospel.

But here is the problem: that guidance was based on the known mechanism of how these drugs work, not on hard outcome data from actual surgical patients. It was a precautionary recommendation — a reasonable one — but not a data-driven conclusion.

Now the data is starting to come in. And it is more reassuring than the early alarm bells suggested.

---

What the New Research Actually Found

A study indexed on PubMed (2025) looked specifically at spine surgery patients — a population that skews older, heavier, and more metabolically complex than average. These are exactly the kinds of patients most likely to be on GLP-1 medications.

The findings were notable. Patients taking GLP-1 receptor agonists did not show higher rates of:

• Surgical site infections
• Wound complications
• 30-day readmissions
• Overall post-operative complications

In plain terms: taking semaglutide or a similar GLP-1 before spine surgery did not appear to make things go worse.

This matters because spine surgery patients are not a low-stakes group. Many have diabetes, obesity, or both — conditions that independently raise surgical risk. The fact that GLP-1 use on top of those conditions still did not shift outcomes is a meaningful signal.

---

The Real Risk That Remains: Aspiration Under Anesthesia

Let us be clear about what the study does not erase.

The aspiration concern is real. GLP-1 drugs reduce how fast your stomach empties, and there are documented case reports of patients having residual stomach contents even after appropriate fasting periods. During intubation, inhaling those contents can cause serious lung injury.

This is not a theoretical risk. It is the reason the original anesthesiology guidance existed.

What has changed is context. Anesthesia teams now have better tools — including extended fasting protocols, point-of-care ultrasound to check gastric content before proceeding, and modified rapid-sequence intubation techniques. The risk is real, but it is increasingly manageable when the care team knows you are on a GLP-1.

The danger is not being on a GLP-1. The danger is not telling your team you are on one.

---

The Decision You Are Actually Trying to Make

Most people reading this are in one of two situations:

Situation A: You are on a GLP-1 for weight management or metabolic health, you have spine surgery scheduled, and your surgeon or anesthesiologist told you to stop your medication 1-2 weeks before the procedure. You are wondering if that is really necessary.

Situation B: You have been managing your weight with a GLP-1 and are worried that stopping before surgery will cause weight regain, blood sugar spikes, or rebound effects that hurt your recovery.

Both of these are legitimate concerns. Here is how to think through them.

---

Who Should Probably Stop Before Surgery (And Who Probably Does Not Need To)

The case for stopping your GLP-1 before surgery

You are a stronger candidate to pause your GLP-1 before spine surgery if:

• You have poorly controlled diabetes and your blood sugar management depends heavily on the GLP-1
• You have a history of gastroparesis or slow gut motility already
• You have had nausea, vomiting, or reflux as side effects of your GLP-1 medication
• Your surgery is longer or more complex (multi-level fusions, revisions)
• Your anesthesia team specifically requests it based on your individual workup

In these cases, stopping 1-2 weeks out — as the ASA originally suggested — gives your stomach time to return to more normal emptying rates and reduces aspiration risk at a time when other risks are already elevated.

The case for staying on your GLP-1 through surgery

You may not need to stop if:

• You are on a GLP-1 primarily for weight management (not blood sugar control) and stopping risks meaningful metabolic disruption
• You have well-controlled diabetes where the GLP-1 is part of a broader stable regimen
• Your surgery is elective, lower-complexity, and your anesthesiologist has confirmed they can manage the aspiration risk with extended fasting or ultrasound assessment
• You experience no GI side effects from your medication, suggesting gastric emptying may be less impacted for you

The spine surgery outcome data supports the idea that being on these medications does not doom the surgery itself. The conversation with your care team is about managing the anesthesia component specifically.

---

What to Actually Say to Your Surgeon

This is the actionable part. If you are on a GLP-1 and have surgery coming up, bring these specific questions to your pre-op appointment:

1. "I'm on [medication name and dose]. Does your anesthesia team have a protocol for managing GLP-1 patients, or will you be doing a gastric ultrasound before proceeding?"

2. "Is there outcome data that supports stopping my medication for my specific procedure, or is this a blanket precautionary recommendation?"

3. "If I stop 1-2 weeks before surgery, what is the plan for managing my blood sugar / metabolic health in the interim?"

4. "When can I restart after surgery, and is there a reason not to restart immediately post-op?"

These questions accomplish two things. They signal to your care team that you are an informed patient. And they push the conversation toward your individual risk profile rather than a one-size-fits-all policy.

---

The Bigger Picture: GLP-1s Are Changing Surgery Risk Math

One thing worth noting: GLP-1 medications do not just affect body weight. They have documented effects on cardiovascular health, metabolic function, and inflammation — all of which matter for surgical recovery.

A patient who has lost 40 pounds on semaglutide and improved their blood sugar control is, in many ways, a better surgical candidate than they were before starting the medication. The net effect of being on a GLP-1 for several months before surgery might actually tilt positive — even accounting for the gastric emptying issue.

Research on GLP-1s and heart failure outcomes, published in the European Heart Journal, found benefits that extend well beyond glucose and weight management. That context matters when calculating the full risk of stopping these medications before surgery versus continuing them.

---

What About Recovery After Spine Surgery?

This is a question that does not get enough attention. Spine surgery recovery often involves reduced mobility, disrupted eating patterns, and post-operative inflammation. That is exactly the environment where metabolic instability can cause problems.

Some researchers are also looking at whether GLP-1 medications might have anti-inflammatory properties that could support surgical recovery — though this is early and speculative territory. What is less speculative: stopping a medication that has been stabilizing your metabolism and then reintroducing it post-surgery adds a layer of variability that may not be worth the trade-off for low-risk procedures.

There is also the muscle loss angle. Research published in 2026 has flagged that GLP-1-induced weight loss can come with some muscle mass reduction, and post-surgical recovery already puts muscle under stress. If you are stopping your GLP-1 and then going into a recovery period with limited mobility, having a plan for protein intake and physical therapy matters more than usual.

---

FAQ

Does Ozempic or Wegovy increase surgery risk? Based on current evidence, being on semaglutide does not appear to increase the risk of spine surgery complications. The primary concern is aspiration risk during anesthesia due to slowed gastric emptying — which is real but manageable with proper anesthesia protocols. Discuss your specific situation with your surgical team.

How long before surgery should I stop my GLP-1? The American Society of Anesthesiologists originally suggested stopping 1-2 weeks before elective surgery. That guidance is evolving as outcome data comes in. Some anesthesiologists now use gastric ultrasound to assess individually rather than applying blanket stopping rules. Ask your anesthesiologist directly — this is not a one-size-fits-all answer.

Can I restart my GLP-1 after spine surgery? In most cases, yes — once you are tolerating oral intake and your care team clears it. There is no evidence that restarting after surgery is harmful. Timing depends on your recovery, post-op nausea, and your individual medication regimen.

What if I stop my GLP-1 before surgery and my blood sugar spikes? This is a legitimate concern, especially for patients with type 2 diabetes. If your care team recommends stopping, ask them specifically what the plan is for blood sugar management in the gap period. Do not just stop without a bridge plan.

Does tirzepatide (Mounjaro/Zepbound) have the same surgery concerns as semaglutide? Yes — tirzepatide also slows gastric emptying and the same aspiration concerns apply. The spine surgery outcome data focuses primarily on GLP-1 class drugs broadly, and tirzepatide as a dual GIP/GLP-1 agonist falls within that category for anesthesia planning purposes.

---

The Bottom Line (Decision Summary)

The research is increasingly clear that being on a GLP-1 receptor agonist does not make spine surgery outcomes worse. The aspiration risk during anesthesia is real — but it is a manageable procedural concern, not a reason to assume your medication is working against you.

The right decision depends on your specific drug, dose, procedure complexity, and whether your anesthesia team has a protocol for GLP-1 patients. A blanket "stop everything" recommendation without individual assessment is becoming harder to justify as the outcome data matures.

Your next step: before your next pre-op appointment, write down which GLP-1 you are on, your dose, and how long you have been taking it. Bring the questions from this article. You are not there to argue with your surgeon — you are there to make sure the decision gets made with your full picture in front of them.

---

Medical Disclaimer: The information on this website is for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide protocol, medication, or supplement regimen. Individual results vary. The author shares personal experience and published research — not medical recommendations.

---

Sources

1. GLP-1 receptor agonist use does not impact spine surgery outcomes — PubMed, 2025
2. GLP-1R agonists and heart failure: novel beneficial effects suggested by Mendelian randomization — European Heart Journal, 2026
3. 15-PGDH inhibition promotes muscle repair and strength recovery during GLP-1 receptor agonist-induced weight loss — PubMed, 2026
4. Beyond weight loss: tirzepatide as a dual GIP/GLP-1 receptor agonist for obstructive sleep apnea — Current Opinion in Endocrinology, Diabetes, and Obesity, 2026
5. Ocular Outcomes with Tirzepatide versus Glucagon-like Peptide-1 Receptor Agonists in Type 2 Diabetes — Ophthalmology Retina, 2026
6. The Paradox and Future of GLP-1/GIP Combination Therapies: Efficacy and Mechanisms — Annual Review of Nutrition, 2026